The MyoRegulator™ PM-2200 is our company’s first product, and provides a breakthrough non-invasive treatment for muscle spasticity. Spasticity is a common condition seen in many patients suffering from stroke, cerebral palsy, multiple sclerosis, spinal cord injury and traumatic brain injury. Management of spasticity is currently a difficult and sometimes insurmountable challenge, and there is tremendous unmet medical need. Pharmacological, surgical, and physical treatments to manage spasticity have, at best, short-term efficacy, are confounded by adverse effects, and are often unpleasant for the patient.
MyoRegulator is based on our proprietary DoubleStim™ technology, which provides simultaneous non-invasive stimulation at spinal and peripheral sites, resulting in suppression of hyperexcitable spinal circuits found in patients with spasticity. Early feasibility clinical use of our DoubleStim™ technology has demonstrated promising results in treating spasticity related to cerebral palsy. IRB-approved human clinical trials are now underway to support regulatory submissions for the MyoRegulator system.